Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business6 October 2016Corporate and M&ADeal watch Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryFourteen London lawyers make the grade as Linklaters promotes 37 to partnershipPinsent Masons promotes 23 new partners, with six in LondonHow Pinsents’ forensic accounting partners doubled their billingsSpread of transatlantic firms in the mix on Unilever’s $45bn food business sale‘The merger is working’ – HSF Kramer on its US corporate pushS&C, Kirkland, Skadden among Q1 M&A leaders as megadeals drive activityDealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealDealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanDeal Watch: activity powers on as Latham and A&O lead on $19bn energy joint venture